Along with our current cash position and an opportunity to sell additional shares to our recently announced APM program. We are sufficiently positioned to continue our plans to enhance our genetic health service and advance our therapeutics programs for 23andMe. Our revenue for the three and nine months ended December 31, 2022 was $67 million and $207 million respectively, representing an increase of 18% and 21% respectively over the same periods in the prior year. Third quarter revenue growth was primarily due to an increase in telehealth services revenue from the Lemonaid acquisition last November. Growth in our subscription services revenue and Personal Genome Service, PGS revenues and an increase in research services revenue primarily related to the GSK collaboration.